Showing 1-10 of 2922 results for "".
Spirituality and Spiritual Care of People With Chronic Neurologic Illness
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/spirituality-and-spiritual-care-of-people-with-chronic-neurologic-illness/35444/Despite the spiritual challenges of living with neurologic illness, interventions are available to help ameliorate distress related to existential issues, self-image concerns, conception of personal identity, interpersonal relationships, and grief.Understanding Dystonia: A Practical Approach to Diagnosis and Management
https://practicalneurology.com/diseases-diagnoses/movement-disorders/understanding-dystonia-a-practical-approach-to-diagnosis-and-management/49157/Clinical history helps corroborate the diagnosis of dystonia and provides clues to its etiology; however, the diagnosis rests on clinical examination, because no gold standard laboratory or imaging tests are available.Fluid Biomarkers in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/fluid-biomarkers-in-multiple-sclerosis/36255/Fluid biomarkers may allow for improvement in diagnosis, prognostication, and monitoring of disease activity and treatment response in multiple sclerosis while reducing reliance on imaging.- Jonathan L. Carter, MDhttps://practicalneurology.com/profiles/jonathan-l-carter-md/Lb06AZ/
Fatigue in Patients With Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/fatigue-in-patients-with-multiple-sclerosis/30212/Treating fatigue in patients with multiple sclerosis may significantly improve quality of life and requires a high index of suspicion for coexisting sleep disorders.- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- FDA Clears L-4-Chlorokynurenine for Phase 2 Trials in Levodopa-Induced Dyskinesiahttps://practicalneurology.com/news/fda-clears-l-4-chlorokynurenine-for-phase-2-trials-in-levodopa-induced-dyskinesia/2469143/The Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for L-4-chlorokynurenine (AV-101, VistaGen Therapeutics, South San Francisco, CA), as a potential treatment for levodopa-induced dyskinesia. The FDA's IND clearance permits the procession of the p
- Award Recipients Recognized at 2025 International MDS Conferencehttps://practicalneurology.com/news/award-recipients-recognized-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/2483939/The International Parkinson’s Disease and Movement Disorders Society (MDS) has recognized recipients of the 2025 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The award
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime
- Prev
- Next